News >

Wingo Weighs in on Surgical Approaches in Ovarian Cancer

Caroline Seymour
Published: Tuesday, May 15, 2018

Shana Wingo, MD

Shana Wingo, MD
Although cytoreduction followed by a platinum-based compound and a taxane agent has been the preeminent method of treatment for patients with ovarian cancer, Shana Wingo, MD, explains that neoadjuvant therapy is becoming more openly adopted in the field.

“Neoadjuvant therapy has sustained a certain dogma in ovarian cancer for years, but there’s been more comfort in foregoing upfront debulking as the data come out in support of the approach,” says Wingo. She notes, that a patient’s comorbidities and cancer may preclude them from receiving surgery upfront.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication